Navigation Links
Morphotek Inc. Pilot Plant Receives 2013 Facility of the Year Award
Date:2/4/2013

EXTON, Pa., Feb. 4, 2013 /PRNewswire/ -- Morphotek® Inc., a subsidiary of Eisai Inc., announced today that its recently opened 60,000-square-foot pilot plant for the production of biological-based therapeutics to support early-stage clinical trials has been designated the 2013 Facility of the Year in the Sustainability category in a competition sponsored by the International Society for Pharmaceutical Engineering (ISPE), INTERPHEX, and Pharmaceutical Processing magazine. The award was bestowed by a panel of experts, consisting of senior-level executives from multiple global pharmaceutical companies, who judged 27 projects from various countries.

The Morphotek pilot plant project was initiated in 2008, with groundbreaking occurring in 2010 and construction being completed in late 2011.  The company invested $80 million in the facility, which encompasses a current Good Manufacturing Practice (cGMP) grade pilot plant and office space for support functions, enabling Morphotek to maximize the efficiencies of its product development process and move closer to its goal of becoming a fully integrated biopharmaceutical company.

"Eisai and Morphotek are committed to developing drugs in a cost-effective manner for our patients, and that is reflected in the design and operation of our energy efficient, state-of-the-art manufacturing facility," said Dr. Philip Sass , Morphotek's Executive Vice President and Chief Operations Officer. "We are honored to receive this prestigious award."

The judges said the Morphotek pilot plant utilized a variety of design and construction features that made it stand out from other entries in the Sustainability category, including the following:

  • It was built on a Brownfield site, giving new life to a previously abandoned and contaminated site through soil remediation and  the demoliti
    '/>"/>

  • SOURCE Morphotek Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. FDA Grants Orphan Drug Status To Morphoteks Amatuximab (MORAb-009)
    2. Bluechiip Receives First Sales Order from ATCC after Completion of Successful Pilot Trial
    3. In Pilot Study, a Peptide Controls Blood Sugar in People with Congenital Hyperinsulinism
    4. Ocular Therapeutix Commences Pilot Phase II Travoprost Punctum Plug Study for the Treatment of Glaucoma
    5. Systagenix begins pilot with ToolsGroup to optimise inventory levels
    6. RIPE Pilot Study Suggests Resveratrol May Improve Cognitive Function In The Elderly
    7. STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress
    8. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
    9. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
    10. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    11. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... market has witnessed robust development with the growth pace keeping ... starter. In 2012, the size of China ... proportion worldwide soaring to 16.3%. It is projected that ... growth rate by around 20% in the upcoming years and ... billion. An integrated membrane industrial system has taken ...
    (Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, ... software solutions, today announced a strategic agreement with QualCare, ... New Jersey regional marketplace.  This agreement ... the health and wellness solutions QualCare brings to its ... the surrounding region. QualCare plans cover ...
    (Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
    Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
    ... 2012 Reportlinker.com announces that a new ... catalogue:   ... Devices http://www.reportlinker.com/p0799254/Pricing-and-Reimbursement-Strategies-for-Medical-Devices.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Facility ... medical devices being purchased within public healthcare ...
    ... Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel ... the TREAT-NMD Advisory Committee on Therapeutics (TACT) has ... dystrophy (DMD), and believes the compound has potential ... global network dedicated to expediting the delivery of ...
    Cached Medicine Technology:Pricing and Reimbursement Strategies for Medical Devices 2Pricing and Reimbursement Strategies for Medical Devices 3Pricing and Reimbursement Strategies for Medical Devices 4Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100 2Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100 3
    (Date:12/19/2014)... December 19, 2014 Eufaula, Oklahoma, located ... Lake Eufaula, the state’s largest lake with more than ... is home to a little more than 3,000 residents, ... on Saturday, the 6th of December. , Featuring Santa, ... through downtown Eufaula on Main Street. Narconon Arrowhead’s ...
    (Date:12/19/2014)... 2014 The Medspa at Hendrick in ... from respected cosmetic brand Juvéderm. Voluma XC treats volume ... The Medspa at Hendrick is pleased to be able ... technology to its clients. , Voluma is the first ... to treat the mid-face and cheek area. This non-invasive ...
    (Date:12/19/2014)... 2014 (HealthDay News) -- The intestinal bacteria that cause ... colitis, may be inherited, researchers report. The findings, ... could help in efforts to prevent the disease and ... the study authors added. "The intestinal bacteria, or ... can have a big impact on your health for ...
    (Date:12/19/2014)... 2014 (HealthDay News) -- Injectable drug users who also ... attempt rate of other substance users, a new study ... with the risk of suicide attempt and completed suicide," ... Montreal, said in a university news release. "However, there ... to know who among substance users were actually more ...
    (Date:12/19/2014)... (HealthDay News) -- Older adults who have lost all their ... people who still have at least some of their teeth, ... tooth loss could provide an early warning of increased risk ... researchers said. However, the findings don,t prove that tooth ... included more than 3,100 participants 60 and older. People with ...
    Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2
    ... The Emergency Nurses Association (ENA) today announced the corporate ... Reno, Nevada on March 4 - 8, 2009.This year,s sponsors ... so pleased that these two companies have chosen to support ... the ENA Leadership Conference," said William T. Briggs, RN, MSN, ...
    ... Home Safety Council(R) and H2otStop(R) Launch Burn Awareness Campaign to ... , WASHINGTON, Feb. 9 New research conducted by ... while most adults in America (82 percent) agree that there ... burns in their home, nearly half (44 percent) say they ...
    ... be weighed against downside, experts say , , MONDAY, ... containing corticosteroids to treat chronic obstructive pulmonary disease (COPD) ... as 70 percent, researchers report. , Inhaled corticosteroids, used ... COPD patients. However, one product that is marketed by ...
    ... of 50 genes can be used to reliably identify ... research conducted at Washington University School of Medicine in ... oncologists can potentially predict the most effective therapy for ... treatment for all patients., "Unlike a widely used genomic ...
    ... WASHINGTON, Feb. 9 The Department of Veterans Affairs (VA) ... called a "Step-Up" -- from March 8 to 14 at ... follow the highest standards for patient safety."The safety of our ... J. Kussman, VA,s Under Secretary for Health. "Therefore, I am ...
    ... LAIYANG, China, Feb. 9 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals ... or the,"Company"), a U.S. pharmaceutical company with ... China, today announced that the American Arbitration,Association ... Capital Research,Group, Inc. ("CRG") to award it ...
    Cached Medicine News:Health News:Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 2Health News:American Families Unaware of Burn Dangers at Home 2Health News:American Families Unaware of Burn Dangers at Home 3Health News:American Families Unaware of Burn Dangers at Home 4Health News:Inhaled Corticosteroids Boost Pneumonia Risk in COPD 2Health News:Inhaled Corticosteroids Boost Pneumonia Risk in COPD 3Health News:Inhaled Corticosteroids Boost Pneumonia Risk in COPD 4Health News:New genomic test can personalize breast cancer treatment 2Health News:New genomic test can personalize breast cancer treatment 3Health News:Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis 2Health News:Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis 3
    Single use trocar with non-conductive sleeves for gaining and maintaining thoracic access., ,THORACOPORT™ devices are trocars used to gain access to the thoracic cavity for use in video assis...
    These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System....
    The VersaStep™ 5 mm and VersaStep™ PLUS Reposable system components for creating each access port are supplied in separate packages....
    VersaStep™ Reposable Sterilization Trays....
    Medicine Products: